Initial trial data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate in MTAP-deleted, RAS-mutant pancreatic cancer patients, with 90% progression-free at six months. The combination was well tolerated with primarily Grade 1/2 adverse events, supporting rapid Phase 3 advancement in first-line MTAP-deleted pancreatic cancer.
As of May 28, 2026, 12 response-evaluable MTAP-deleted, RAS-mutant PDAC patients treated with vopimetostat 200 mg or 250 mg plus daraxonrasib 100 mg once daily achieved a 92% objective response rate, with 90% progression-free at six months and a 100% disease control rate. In a small NSCLC cohort (n=3), all patients achieved confirmed responses.
The vopimetostat plus daraxonrasib combination showed a manageable safety profile with most treatment-related adverse events at Grade 1 or 2, including rash, stomatitis and diarrhea. No Grade 4 or 5 events were reported, and dose-limiting toxicities occurred only at the higher dose level, leading to three dose reductions without discontinuations.
Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib regimen into a randomized Phase 3 trial in first-line MTAP-deleted pancreatic cancer in the second half of 2026, pending regulatory feedback. Upcoming milestones include finalizing trial design, disclosing lung cancer monotherapy data in 2H 2026 and initiating additional combination studies in glioblastoma and other indications.
